In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: Evidence for sequence-dependent effects

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 2, 2011, Pages 265-273

  Zanellato, Ilaria ^a   Boidi, Carla Doriana ^a   Lingua, Guido ^a   Betta, Pier Giacomo ^b   Orecchia, Sara ^b   Monti, Elena ^c   Osella, Domenico ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b C Arrigo Children's Hospital   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Cisplatin; Combination chemotherapy; Gemcitabine; Malignant pleural mesothelioma

Indexed keywords

CISPLATIN; GEMCITABINE; PROTEIN P53; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; DNA ADDUCT; DOUBLE STRANDED DNA BREAK; DRUG ANTAGONISM; DRUG POTENTIATION; HISTOPATHOLOGY; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; APOPTOSIS; CELL SURVIVAL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; DRUG RESISTANCE; IC 50; MESOTHELIOMA; PLEURA TUMOR; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DEOXYCYTIDINE; DNA BREAKS, DOUBLE-STRANDED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; INHIBITORY CONCENTRATION 50; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 79953800571     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1314-0     Document Type: Article

References (38)

1. Montanaro F, Rosato R, Gangemi M, Roberti S, Ricceri F, Merler E, Gennaro V, Romanelli A, Chellini E, Pascucci C, Musti M, Nicita C, Barbieri PG, Marinaccio A, Magnani C, Mirabelli D (2009) Survival of pleural malignant mesothelioma in Italy: a population-based study. Int J Cancer 124:201-207
2. Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, Meert AP, Sculier JP (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38:111-121 (Pubitemid 35157753)
3. Kindler HL (2008) Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol 9:171-179
4. Green J, Dundar Y, Dodd S, Dickson R, Walley T (2007) Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma (Review). Cochrane Database Syst Rev 2:1-17
5. Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, Keohan ML, Taub RN, Borden EC (2008) Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 60:259-263 (Pubitemid 351609140)
6. Utkan G, Büyükçelik A, Yalçin B, Akbulut H, Demirkazik A, Dinçol D, Onur H, Gören D, Mousa U, Senler FC, Içli F (2006) Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma. Lung Cancer 53:367-374 (Pubitemid 44192595)
7. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ (1996) Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2:521-530 (Pubitemid 26099172)
8. Padrón JM, van Moorsel CJ, Bergman AM, Smitskamp-Wilms E, van der Wilt CL, Peters GJ (1999) Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures. Anticancer Drugs 10:445-452
9. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds) (2004) World Health Organization Classification of Tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. IARC Press, Lyon
10. Orecchia S, Schillaci F, Salvio M, Libener R, Betta PG (2004) Aberrant E-cadherin and gamma-catenin expression in malignant mesothelioma and its diagnostic and biological relevance. Lung Cancer 45 S: S37-S43 (Pubitemid 38917112)
11. Sigalotti L, Coral S, Altomonte M, Natali L, Gaudino G, Cacciotti P, Libener R, Colizzi F, Pianale G, Martini F, Tognon F, Jungbluth A, Cebon J, Maraskovsky E, Mutti L, Maio M (2002) Cancer testis antigens expression in mesothelioma. Br J Cancer 86:979-982
12. Toma S, Colucci L, Scarabelli L, Scaramuccia A, Emionite L, Betta PG, Mutti L (2002) Synergistic effect of the anti-HER-2/neu antibody and cisplatin in immortalized and primary mesothelioma cell lines. J Cell Physiol 193:37-41 (Pubitemid 34969126)
13. Mantel N (1958) An experimental design in combination chemotherapy. Ann NY Acad Sci 76:909-931
14. Sevin BU, Peng ZL, Perras JP, Ganjei P, Penalver M, Averette HE (1988) Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 31:191-204
15. Marchevsky AM (2008) Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med 132:397-401 (Pubitemid 351328814)
16. Reiss M, Brash DE, Muñoz-Antonia T, Simon JA, Ziegler A, Vellucci VF, Zhou ZL (1992) Status of the p53 tumor suppressor gene in human squamous carcinoma cell lines. Oncol Res 4:349-357 (Pubitemid 23167119)
17. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
18. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304-6311
19. Shieh SY, Ikeda M, Taya Y, Prives C (1997) DNA damageinduced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334 (Pubitemid 27467963)
20. Pietsch EC, Sykes SM, McMahon SB, Murphy ME (2008) The p53 family and programmed cell death. Oncogene 27:6507-6521
21. Budzowska M, Kanaar R (2009) Mechanisms of dealing with DNA damage-induced replication problems. Cell Biochem Biophys 53:17-31
22. van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, Peters GJ (1999) Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer 35:808-814 (Pubitemid 29258152)
23. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM (2007) Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 7:3-18 (Pubitemid 46062402)
24. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17 (Suppl 5): v7-v12 (Pubitemid 43994854)
25. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′, 2′-difluorodeoxycytidine. Mol Pharmacol 38:567-572 (Pubitemid 20356209)
26. Peters GJ, Van Moorsel CJ, Lakerveld B, Smid K, Noordhuis P, Comijn EC, Weaver D, Willey JC, Voorn D, Van der Vijgh WJ, Pinedo HM (2006) Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or-resistant human ovarian cancer cell lines. Int J Oncol 28:237-244
27. van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ (1999) Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 80:981-990 (Pubitemid 29233918)
28. Karagiannis TC, El-Osta A (2004) Double-strand breaks: signaling pathways and repair mechanisms. Cell Mol Life Sci 61:2137-2147 (Pubitemid 39280110)
29. Yang LY, Li L, Jiang H, Shen Y, Plunkett W (2000) Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 6:773-781 (Pubitemid 30159329)
30. Crul M, van Waardenburg RC, Bocxe S, van Eijndhoven MA, Pluim D, Beijnen JH, Schellens JH (2003) DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 65:275-282 (Pubitemid 36015830)
31. Bergstralh DT, Sekelsky J (2008) Interstrand crosslink repair: can XPF-ERCC1 be let off the hook? Trends Genet 24:70-76
32. Voigt W, Bulankin A, Müller T, Schoeber C, Grothey A, Hoang-Vu C, Schmoll HJ (2000) Schedule dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Canc Res 6:2087-2093 (Pubitemid 30305109)
33. Miyagawa K (2008) Clinical relevance of the homologous recombination machinery in cancer therapy. Cancer Sci 99:187-194 (Pubitemid 351228469)
34. Sorenson CM, Eastman A (1988) Influence of cis-diamminedichloroplatinum (II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 48:6703-6707 (Pubitemid 19012192)
35. Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S, Kohno M (2008) Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci 99:376-384 (Pubitemid 351228495)
36. Donadelli M, Costanzo C, Beghelli S, Scupoli MT, Dandrea M, Bonora A, Piacentini P, Budillon A, Caraglia M, Scarpa A, Palmieri M (2007) Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 1773:1095-1106 (Pubitemid 46898677)
37. Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L (2009) Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 8:2818-2828
38. Osella D et al. (in preparation)